CRDF (Cardiff Oncology) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Cardiff Oncology LT-Debt-to-Total-Asset?

Cardiff Oncology CRDF +1.56% 53 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates CRDF with a GF Score™ of 53/100 and a GF Value™ of $1.48 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Cardiff Oncology's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Cardiff Oncology's long-term debt to total assets ratio declined from Mar. 2025 (0.01) to Mar. 2026 (0.00). It may suggest that Cardiff Oncology is progressively becoming less dependent on debt to grow their business.

Cardiff Oncology (NAS:CRDF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Cardiff Oncology LT-Debt-to-Total-Asset Related Terms

Cardiff Oncology LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology LT-Debt-to-Total-Asset Chart

Cardiff Oncology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.01

0.00

Cardiff Oncology Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.01	0.01	0.00	0.00	0.00

53GF Score

Cardiff Oncology Inc CRDF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cardiff Oncology LT-Debt-to-Total-Asset Calculation

Cardiff Oncology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.102	/	61.884
	=	0.00

Cardiff Oncology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0	/	49.172
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Cardiff Oncology (CRDF) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cardiff Oncology and its competitors.

Is Cardiff Oncology's LT-Debt-to-Total-Asset too high?

Cardiff Oncology's current LT-Debt-to-Total-Asset is 0.00. Overall, Cardiff Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Cardiff Oncology's LT-Debt-to-Total-Asset compare to MAIA and TELO?

Cardiff Oncology's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cardiff Oncology stock overvalued right now?

Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.48, compared to a current price of $1.30 — trading 12.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Cardiff Oncology's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cardiff Oncology (CRDF) Overvalued in 2026?

Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued. The current stock price of $1.30 is trading 12.2% below its estimated GF Value™ of $1.48. GuruFocus considers Cardiff Oncology to be Modestly Undervalued.

Key valuation signals for CRDF:

LT-Debt-to-Total-Asset: 0.00
GF Value™: $1.48 vs. price of $1.30 (12.2% below fair value)
GF Score™: 53/100 with 4 warning signs

No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cardiff Oncology Business Description

Industry Healthcare Biotechnology

Comparable Companies MAIA TELO OSTX LONA RNTX IBIO RANI ICCC OKYO PYPD VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges XE7C:Germany

Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

53GF Score

Get the complete analysis for CRDF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.30

Price

$1.48

GF Value

View CRDF Analysis

See LT-Debt-to-Total-Asset data for all stocks →